Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study

Journal of Ultrasonography · Published 2026-06-30 · DOI 10.15557/jou.2026.0016

Free full text

Authors (6)

Gianvito Barbella, Pietro Antenucci, Vittorio Govoni, Ilaria Casetta, Maurizio Paciaroni, Marina Padroni

Abstract

Migraine is the second most disabling condition worldwide. Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway represent an effective prophylactic treatment; however, their impact on cerebral hemodynamics remains unclear. The aim of this pilot study was to evaluate cerebrovascular risk in patients with migraine without aura treated with these therapies, by calculating the breath-holding index (BHI) of the anterior cerebral circulation using transcranial color-coded Doppler (TCCD) ultrasonography.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2026

Citation

Barbella, G., Antenucci, P., Govoni, V., et al. (2026). Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study. Journal of Ultrasonography. https://doi.org/10.15557/jou.2026.0016

Related articles